ESMO 2012: GDC-0973 against melanoma in the United vemurafenib
September 28 - October 2, 2012 Annual Meeting of the European Society of Medical Oncology (ESMO 2012) in the Austrian capital Vienna.
A phase Ⅰ study, MEK inhibitor GDC-0973 can be safely administered jointly vemurafenib, the University of Colorado Cancer Center, Dr. Rene Gonzalez and his colleagues report.
"BRAF inhibition of BRAF mutation can greatly improve remission rates in patients with melanoma and improve living conditions," Gonzalez said, "BRAF inhibitor resistance mechanism is one of the MAPK pathway reactivation. Preclinical models show that combined inhibition of BRAF and MEK than a simple BRAF inhibition can delay drug resistance. theoretically, the use of MEK inhibitor GDC-0973 inhibit the BRAF pathway downstream can overcome or delay resistance, thereby improving the prognosis. "
The intention is not to assess the efficacy study. "But the preliminary data showed tumor shrinkage, but based on the results of the preliminary study is too early to assess the efficacy, there is need for further research," Gonzalez said Dr.
ESMO 2012: GDC-0973 against melanoma in the United vemurafenib
ReplyDeleteSeptember 28 - October 2, 2012 Annual Meeting of the European Society of Medical Oncology (ESMO 2012) in the Austrian capital Vienna.
A phase Ⅰ study, MEK inhibitor GDC-0973 can be safely administered jointly vemurafenib, the University of Colorado Cancer Center, Dr. Rene Gonzalez and his colleagues report.
"BRAF inhibition of BRAF mutation can greatly improve remission rates in patients with melanoma and improve living conditions," Gonzalez said, "BRAF inhibitor resistance mechanism is one of the MAPK pathway reactivation. Preclinical models show that combined inhibition of BRAF and MEK than a simple BRAF inhibition can delay drug resistance. theoretically, the use of MEK inhibitor GDC-0973 inhibit the BRAF pathway downstream can overcome or delay resistance, thereby improving the prognosis. "
The intention is not to assess the efficacy study. "But the preliminary data showed tumor shrinkage, but based on the results of the preliminary study is too early to assess the efficacy, there is need for further research," Gonzalez said Dr.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Lurasidone Hydrochloride
Adoprazine
Rotigotine
Rotigotine hydrochloride
HOKU-81
Olmesartan
Olmesartan medoxomil
BML-190
AM630
Adoprazine